Scientific article

Pathogenesis-oriented therapy of psoriasis using biologics

Published inExpert opinion on biological therapy, vol. 22, no. 12, p. 1463-1473
First online date2022-07-20

Introduction: Psoriasis is currently regarded an immune-mediated inflammatory disease. The central pathogenic axis comprises interleukin-23, TH17-lymphocytes differentiating under its influence, and interleukin-17A as a key effector cytokine of these T-lymphocytes. All of these can selectively be targeted using biological therapies, thus potentially increasing efficacy and reducing adverse events when compared to conventional systemic therapeutics.

Areas covered: We review the current concept of psoriasis as an immune-mediated inflammatory disease, assessing the evidence for a role of elements of the innate and adaptive immune system. We then correlate the pharmacological effects of biologics in psoriasis in light of the known physiologic as well as pathophysiological role of the respective targets. This is done on the basis of an extensive literature search of publications since 2018 which describe the role of the above-mentioned elements in health and disease or the effects of blocking these as an attempt to treat psoriasis.

Expert opinion: Biologics targeting the above-mentioned central pathogenic axis provide a particularly effective and safe way to treat psoriasis. Given the impact of comorbidities on therapeutic decision-making, and the efficacy of some biologics also on certain comorbidities, these drugs represent a first step toward personalized medicine in the management of psoriasis.

  • Biologics
  • TH17-lymphocytes
  • Comorbidity
  • Personalized medicine
  • Psoriasis
  • Regulatory T-lymphocytes
  • Therapy
  • Tissue-resident memory T-cells
  • Humans
  • Biological Products / adverse effects
  • Th17 Cells
  • Psoriasis / pathology
  • Biological Factors / therapeutic use
  • Interleukin-23
Citation (ISO format)
BOEHNCKE, Wolf-Henning, BREMBILLA, Nicolo. Pathogenesis-oriented therapy of psoriasis using biologics. In: Expert opinion on biological therapy, 2022, vol. 22, n° 12, p. 1463–1473. doi: 10.1080/14712598.2022.2100219
Main files (1)
Article (Published version)
ISSN of the journal1471-2598

Technical informations

Creation02/03/2023 2:55:00 PM
First validation02/03/2023 2:55:00 PM
Update time03/16/2023 10:38:50 AM
Status update03/16/2023 10:38:49 AM
Last indexation02/01/2024 9:36:15 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack